To observe the effects of different treatments on the oncological outcome and complications of early cervical cancer (2018 FIGO stage IA1 with lymphovascular space invasion and IA2-IIA2 cervical cancer). This study prospectively collecting enrolled cervical cancer patients clinical data and outcome from June 2020 to June 2025. (Classification factors: preoperative neoadjuvant treatment , surgical approach, type of hysterectomy, whether to receive radiochemotherapy) . This study is an observational study, and segmented analysis according to different treatment methods.
Objectives: To observe the effects of different treatments on the oncological outcome and complications of early cervical cancer (2018 FIGO stage IA1 with lymphovascular space invasion and IA2-IIA2 cervical cancer). Study Design: We obtained the demographic, clinical, treatment hospital and complication data of patients with cervical cancer undergoing radical hysterectomy from 2004 to 2015 at 37 hospitals. The patients were assigned into groups. Classification factors: preoperative neoadjuvant treatment (not received, neoadjuvant chemotherapy, preoperative radiotherapy) , surgical approach (abdomincal, laparoscopic, vaginal, robotic surgery), type of hysterectomy (type B, type C1, type C2), primary treatment (radiochemotherapy or surgery). laparoscopic and abdominal surgery groups. The differences in the survival, complication rates, quality of life, and cost were analyzed using univariate and multivariable logistic regression models.
Study Type
OBSERVATIONAL
Enrollment
20,000
The cohort stratified by four factors: preoperative treatment (not received, neoadjuvant chemotherapy, preoperative radiotherapy); surgical approach (laparoscopic, abdominal, vaginal, robotic); hysterectomy types (type A, type B, type C1, type C2), primary treatment (Radical hysterectomy + pelvic lymph node dissectionp; radiochemotherapy)
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China
RECRUITINGOverall survival (OS)
Overall survival was defined as the period from initial treatment until cervical cancer related death.
Time frame: 60 months from primary treatment
disease-free survival (DFS)
Tumor-free survival was defined as the period from initial treatment until the recurrence or the date of last follow-up.
Time frame: 60 months from primary treatment
Patterns of recurrence
date and localization of 1st recurrence as confirmed histologically
Time frame: 60 months from primary treatment
Costs of treatment
Time frame: 60 months from primary treatment
Costs of readmission
Time frame: 60 months from primary treatment
Quality of life Questionnaires
The European O-rganization for Reasearch and Treatment of Cance QLQ-30 Questionnaires to measure quality of life for any kind cancer patient. The Europe Organization for Research and Treatment of Cancer, Quality of Life Questionnaire Cervical Cancer Module is a supplementary questionnaire for evaluating the quality of life of patients with cervical cancer.
Time frame: 60 months from primary treatment
The morbidity of sexual dysfunction
Female Sexual Function Index (FSFI)
Time frame: 60 months from primary treatment
Intra-operative, peri-operative, post-operative and long term treatment related morbidity
Complications of all the patients
Time frame: 60 months from primary treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.